Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
   
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  SWAN Knowledge Base
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Pathways
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Have APP, Will Travel
Part 9 of our 11-part Eibsee conference series. See also Parts 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, and complete PDF.

Cell culture studies notwithstanding, in the brain, the presynaptic terminals of neurons are thought to be a main source of Aβ, and a controversy is simmering in the field about exactly how it gets there. One view, advanced by Larry Goldstein at University of California, San Diego, proposes that some is generated in transport vesicles traveling down the axon to the nerve terminal. In a nutshell, this research suggests that APP anchors cargo vesicles to the motor protein kinesin, either directly or via linker proteins in a complex, and that one and the same vesicle tends to contain all necessary components of APP γ cleavage. Axonal transport blockages would drive up Aβ generation because the components would dwell together in the vesicles longer (see Stokin and Goldstein, 2006; Stokin et al., 2005; Kamal et al., 2001; Alzforum axonal transport discussion). A collaboration of scientists from several groups has been unable to reproduce some of the data, leaving the issue open (see Lazarov et al., 2005; Zheng comment there, and Goldstein reply).

At the Eibsee, two speakers reported that they tested Goldstein’s hypothesis with various cell-based approaches but found no support for it. Stefan Kins, at Heidelberg University, Germany, was a coauthor of Lazarov et al., 2005, and has since run further experiments. In the paper, the authors had suggested that a reported interaction between APP’s cytoplasmic tail and the light chain of kinesin might be nonspecific. At the conference, Kins added that he searched for APP/kinesin complexes with coimmunoprecipitation of mouse brain lysates to examine the idea that APP might interact indirectly with kinesin through a cytoplasmic linker, but detected no such complexes. These approaches still leave open the possibility of an indirect association between APP and kinesin mediated through scaffolding proteins such as JIP. JIP1 has been suggested to couple APP-containing vesicles to kinesin motors (see, e.g., Matsuda et al., 2003), and could conceivably do so through its interaction with the NPTY internalization motif on APP’s cytoplasmic tail. To test this directly, Kins used siRNA to knock down JIP1 in cultures of cortical primary neurons, and found that the neurons transported most of their APP from the ER out to neurites regardless of how much JIP1 they had available. JIP might link a small pool of APP to kinesin, but for the bulk of APP the kinesin linker remains elusive, Kins said. Its linker need not even interact with its cytoplasmic tail, as an APP mutant lacking that piece still traveled out to neurites unperturbed.

Finally, Kins noted that APP, APLP1, and APLP2 are transported to different sections of the cell membrane. APLP1 resides primarily in dendritic, postsynaptic membranes, and APLP2 in presynaptic areas and growth cones, where each forms dimers with APP (Soba et al., 2006). For this reason, Kins suggested that each family member may travel in its own type of vesicle, using a different linker protein to a different subset of kinesin motor, and that this helps direct their specific route of transport.

Claire Goldsbury, who works with Eva-Maria Mandelkow at the Max-Planck Unit for Structural Molecular Biology in Hamburg, approached the issue from a different angle. She is interested in the relationship between tau and APP in axonal transport. Goldsbury tested the proposal that APP/BACE/γ-secretase travel in the same vesicles and are cleaved en route. First, she asked whether blocking APP transport in cultured neurons would increase Aβ production. She cultured rat primary neurons, transfected them with a Swedish APP-YFP construct, imaged the neurons, and measured how much Aβ they contained and secreted. As expected based on prior work from Mandelkow’s group, Goldsbury saw that overexpressing tau gummed up the microtubules and blocked the transport of APP from the nucleus out to the neuron’s tips. As planned, this lengthened the time APP vesicles spent in transit, yet Aβ levels never increased, indicating the APP does not get cleaved in transit. This was shown directly by double-labeling APP at both ends with YFP and CFP and watching the ratio of colors during vesicle movement. The ration did not change, indicating that APP molecules remained intact (Goldsbury et al., Traffic, 2006, in press).

Next, Goldsbury reported that vesicles containing APP and BACE move quite differently in culture. APP vesicles move swiftly down the neuron’s processes, whereas BACE vesicles tended to “dawdle,” moving forward a bit, then back, and taking lots of stationary breaks in between. Cotransfection of both APP (labeled yellow) and BACE (labeled red) showed little overlap in vesicles. At the Keystone conference earlier this year, Mandelkow already reported that APP and BACE reside in different vesicles (see ARF conference story).—Gabrielle Strobel.

 
Comments on Related News
Related News: Trisomy Trouble: Neurotrophin Signaling Defective in Down Syndrome

Comment by:  Lino Tessarollo
Submitted 11 July 2006 Posted 11 July 2006

I think this study by Salehi and colleagues complements our work. If anything, the two studies combined stress once again the relevance of neurotrophin supply/signaling in supporting neuronal survival and function. What I find intriguing is that the two papers describe different mechanisms by which alterations in neurotrophin signaling can cause neuronal cell death, depending on the specific brain cell type affected. For example, Salehi et al. report that disrupted retrograde transport of NGF to the basal forebrain cholinergic neurons (BFCNs) causes degeneration of these neurons (I would like to note that BDNF is not a major signaling molecule in this neuronal cell population, which is why Salehi et al. find that the retrograde transport of BDNF and NT3 is below the limits of detection with the methodology used in their study). We find that an impairment of TrkB signaling causes cell death in cortical and hippocampal neurons, two cell populations that are responsive to BDNF and in which TrkB receptor isoforms alterations have been already described in Alzheimer disease (AD). As...  Read more

View all comments by Lino Tessarollo

Related News: Trisomy Trouble: Neurotrophin Signaling Defective in Down Syndrome

Comment by:  Bai Lu
Submitted 11 July 2006 Posted 11 July 2006

NGF has a potent effect on cholinergic neurons in the basal forebrain, which are prone to degeneration in AD. The idea that NGF dysfunction is involved in AD has been around for some time, but it has never been taken seriously because of the prominence of the “Aβ” hypothesis. Now Mobley and colleagues show that APP acts to reduce the retrograde transport of NGF in these cholinergic neurons, a process that might be important for their survival. The significance of the work by Mobley et al. is that they provide a mechanistic link between APP and NGF signaling in the basal forebrain neurons, therefore putting NGF back into the center stage of the AD field. The immediate task now is to test whether this works in an AD model.

The functional role of TrkB.T1, which is highly expressed in the brain, has been puzzling for some time now. One idea is that T1 has no function by itself, but prevents locally secreted BDNF from diffusion to distant places, and therefore ensures its local action. Another idea is that T1 can actually signal in glial cells in an unconventional way, but...  Read more

View all comments by Bai Lu


Related News: Trisomy Trouble: Neurotrophin Signaling Defective in Down Syndrome

Comment by:  Volkmar Lessmann
Submitted 14 July 2006 Posted 14 July 2006

Yano and colleagues managed to proceed one step further in elucidating synaptic actions of neurotrophins. Although it was well established for quite some time that BDNF exerts presynaptic effects on the availability of presynaptic glutamate vesicles for synaptic transmission, the molecular determinants of this action were far from being understood. This paper now highlights new downstream signaling partners in the presynaptic actions of BDNF.

The observation, in the early 1990s, that BDNF can enhance presynaptic functions of excitatory synapses (Lohof et al., 1993; Lessmann et al., 1994) was followed shortly thereafter by the discovery of an essential role of BDNF in Schaffer collateral LTP (Korte et al., 1995; Patterson et al., 1996). Also, in 1996, Figurov and colleagues (1996) found that one of the important presynaptic actions of BDNF is to avoid transmitter vesicle depletion upon repetitive activity of juvenile synapses, although this presynaptic BDNF effect cannot account for the impaired LTP in adult animals. It took another four years to learn, from the data by...  Read more

View all comments by Volkmar Lessmann

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2010 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad